Eli Lilly’s latest $1.4 billion deal might come unglued

Eli Lilly wants to pay $1.4 billion for Point Biopharma, maker of cancer drugs that deliver a focused dose of radiation to tumor cells. But Point’s shareholders don’t seem to want to sell, and it’s becoming a problem.